Adjuvant Therapy for Cutaneous Melanoma

Darryl Schuitevoerder; Charles C. Vining; Jennifer Tseng

doi:10.1016/j.soc.2020.02.009

Adjuvant Therapy for Cutaneous Melanoma

Darryl Schuitevoerder, Charles C. Vining, Jennifer Tseng

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

This article presents the current data supporting adjuvant therapy for patients with cutaneous melanoma. With the recent development of novel immunotherapy agents as well as targeted therapy, there are strong data to support the use of these therapies in patients at high risk of developing recurrent or metastatic disease.

Original language	English (US)
Pages (from-to)	455-465
Number of pages	11
Journal	Surgical Oncology Clinics of North America
Volume	29
Issue number	3
DOIs	https://doi.org/10.1016/j.soc.2020.02.009
State	Published - Jul 2020

All Science Journal Classification (ASJC) codes

Surgery
Oncology

Access to Document

10.1016/j.soc.2020.02.009

Cite this

@article{ff2cf1f87d7c47afbc5ad2ae0815f25c,

title = "Adjuvant Therapy for Cutaneous Melanoma",

abstract = "This article presents the current data supporting adjuvant therapy for patients with cutaneous melanoma. With the recent development of novel immunotherapy agents as well as targeted therapy, there are strong data to support the use of these therapies in patients at high risk of developing recurrent or metastatic disease.",

author = "Darryl Schuitevoerder and Vining, {Charles C.} and Jennifer Tseng",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = jul,

doi = "10.1016/j.soc.2020.02.009",

language = "English (US)",

volume = "29",

pages = "455--465",

journal = "Surgical Oncology Clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders",

number = "3",

}

TY - JOUR

T1 - Adjuvant Therapy for Cutaneous Melanoma

AU - Schuitevoerder, Darryl

AU - Vining, Charles C.

AU - Tseng, Jennifer

PY - 2020/7

Y1 - 2020/7

N2 - This article presents the current data supporting adjuvant therapy for patients with cutaneous melanoma. With the recent development of novel immunotherapy agents as well as targeted therapy, there are strong data to support the use of these therapies in patients at high risk of developing recurrent or metastatic disease.

AB - This article presents the current data supporting adjuvant therapy for patients with cutaneous melanoma. With the recent development of novel immunotherapy agents as well as targeted therapy, there are strong data to support the use of these therapies in patients at high risk of developing recurrent or metastatic disease.

UR - http://www.scopus.com/inward/record.url?scp=85085493265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085493265&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2020.02.009

DO - 10.1016/j.soc.2020.02.009

M3 - Review article

C2 - 32482320

AN - SCOPUS:85085493265

SN - 1055-3207

VL - 29

SP - 455

EP - 465

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

IS - 3

ER -

Adjuvant Therapy for Cutaneous Melanoma

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this